Comparing Intra-Umbilical Versus Intravenous Oxytocin in Women During the Third Stage of Labor for Reducing Blood Loss

What Was Tested

In this phase 4 trial, researchers set out to test Oxytocin.

The third stage of labor is the period between the birth of the baby and the delivery of the placenta.

It had two arms (groups): Intravenous Oxytocin (active comparator) and Intraumbilical Oxytocin (experimental).

The registry classes the interventions as drug.

Who Took Part

60 actual participants took part.

It was open to women only aged from 20 years up to 40 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Gestational age 36 - 42 weeks (on LMP). In spontaneous labour.

The full record lists 2 inclusion and 10 exclusion criteria; among the exclusions: chronic hypertension; multiple pregnancies; preterm or postdates pregnancy.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

The Oxytocin group and the comparison group ran side by side rather than switching.

In this single-blind Oxytocin study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2025-08-13 with completion listed for 2026-02-12.

It ran at 1 site in Pakistan.

Its stated primary purpose is prevention.

What Was Measured

The main thing measured (primary outcome): Mean Blood Loss During the Third Stage of Labor and Within the First 24 Hours After Vaginal Delivery (time frame: From delivery of the baby until 24 hours postpartum).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Oxytocin in 60 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Oxytocin compound page, all human trials.